High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients

In preclinical models, statins showed vaccine adjuvant activities and synergized with PD-1 inhibitors. We analyzed the impact of statin treatment on clinical outcome in thoracic cancer patients treated with PD-1 inhibitors. A total of 82 malignant pleural mesothelioma (MPM) and 179 advanced non-smal...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2021-02, Vol.144, p.41-48
Main Authors: Cantini, Luca, Pecci, Federica, Hurkmans, Daan P., Belderbos, Robert A., Lanese, Andrea, Copparoni, Cecilia, Aerts, Sophie, Cornelissen, Robin, Dumoulin, Daphne W., Fiordoliva, Ilaria, Rinaldi, Silvia, Aerts, Joachim G.J.V., Berardi, Rossana
Format: Article
Language:English
Subjects:
Chemotherapy
Correlation analysis
Immunotherapy
Impact analysis
Inhibitors
Lung cancer
Mesothelioma
Nivolumab
Non-small cell lung carcinoma
Patients
PD-1 protein
Pembrolizumab
Small cell lung carcinoma
Statin
Statins
Survival
Thorax
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In preclinical models, statins showed vaccine adjuvant activities and synergized with PD-1 inhibitors. We analyzed the impact of statin treatment on clinical outcome in thoracic cancer patients treated with PD-1 inhibitors. A total of 82 malignant pleural mesothelioma (MPM) and 179 advanced non-small cell lung cancer (aNSCLC) patients treated with PD-1 inhibitors as second or further line treatment were examined. Seventy-seven MPM patients treated with standard chemotherapy were analyzed as control cohort. Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were calculated. Among 253 patients with available data, statin use was associated with increased ORR (32% versus 18%, P = .02), PFS (median 6.7 versus 2.9 months, hazard ratio [HR] 0.57, 95% CI 0.39–0.83, P 
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2020.10.031